Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with
1Department of Gastroenterology, Qilu Hospital, School of medicine, Shandong University, Jinan 250012, PR China. dcbq@sohu.com
Insights
High mobility group box chromosomal protein 1 (HMGB1) is elevated in hepatocellular carcinoma, correlating with tumor progression and prognosis. HMGB1 may serve as a valuable biomarker and therapeutic target for liver cancer.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- The role of High Mobility Group Box Chromosomal Protein 1 (HMGB1) in hepatocellular carcinoma (HCC) pathogenesis remains largely unelucidated.
- HMGB1 is a nuclear protein with extracellular functions implicated in inflammation and immunity.
Purpose of the Study:
- To investigate the contribution of HMGB1 in hepatocellular carcinoma.
- To analyze the correlation between HMGB1 levels and clinicopathological outcomes in HCC patients.
Main Methods:
- Serum HMGB1 levels were quantified using Western blot analysis.
- Clinicopathological variables including Edmondson grade, TNM stage, and Cancer of the Liver Italian Program (CLIP) score were assessed.
Main Results:
- Serum HMGB1 levels were significantly elevated in HCC patients compared to those with chronic hepatitis, liver cirrhosis, and healthy controls (p < 0.0001).
- HMGB1 showed a positive correlation with alpha-fetoprotein (r = 0.952, p < 0.0001) and tumor size (r = 0.904, p < 0.0001).
- Significant differences in HMGB1 levels were observed across various Edmondson grades, TNM stages, and CLIP scores (p < 0.0001).
Conclusions:
- HMGB1 may serve as a valuable biomarker for assessing tumor stage and predicting prognosis in hepatocellular carcinoma.
- Targeting HMGB1 production or release presents a potential therapeutic strategy for HCC treatment.
Background/Aims:
The role of high mobility group box chromosomal protein 1 in hepatocellular carcinoma is unknown. The aim of study was to evaluate contributions of high mobility group box chromosomal protein 1 in hepatocellular carcinoma, and analyse the correlation between high mobility group box chromosomal protein 1 and clinicopathologic outcomes.
Patients/Methods:
High mobility group box chromosomal protein 1 levels were analysed by Western blot analysis. Edmondson grade, TNM stage and the Cancer of the Liver Italian Program score were used as analysis variables.
Results:
The serum high mobility group box chromosomal protein 1 levels in hepatocellular carcinoma (84.2 +/- 50.4 ng/ml) was significantly higher than those in chronic hepatitis (39.8 +/- 10.5 ng/ml), liver cirrhosis (40.2 +/- 11.6 ng/ml) and healthy control (7.0 +/- 5.9 ng/ml, p < 0.0001, respectively), and positive correlation were found between high mobility group box chromosomal protein 1 and alpha-fetoprotein (r = 0.952, p < 0.0001), and between high mobility group box chromosomal protein 1 and the size of tumour (r = 0.904, p < 0.0001). High mobility group box chromosomal protein 1 were significant differences among Edmondson grade I, II, III, IV; TNM stage I, II, III, IV and Cancer of the Liver Italian Program score 0-1 points, 2-4 points, > 4 points (p < 0.0001, respectively).
Conclusions:
These results suggest that high mobility group box chromosomal protein 1 may be a useful marker for evaluating the tumour stage and predicting prognosis in hepatocellular carcinoma. Targeting high mobility group box chromosomal protein 1 production or release might have potential approaches for hepatocellular carcinoma treatment.
